Cargando…

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

BACKGROUND: Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated. METHODS: CDKN2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helgadottir, Hildur, Ghiorzo, Paola, van Doorn, Remco, Puig, Susana, Levin, Max, Kefford, Richard, Lauss, Martin, Queirolo, Paola, Pastorino, Lorenza, Kapiteijn, Ellen, Potrony, Miriam, Carrera, Cristina, Olsson, Håkan, Höiom, Veronica, Jönsson, Göran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Cancer Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231460/ https://www.ncbi.nlm.nih.gov/pubmed/30291219 http://dx.doi.org/10.1136/jmedgenet-2018-105610

Ejemplares similares

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
por: Helgadottir, Hildur, et al.
Publicado: (2014)

Functional analysis of a CDKN2A 5’UTR germline variant associated with pancreatic cancer development
por: Bruno, William, et al.
Publicado: (2017)

The genetics of uveal melanoma: current insights
por: Helgadottir, Hildur, et al.
Publicado: (2016)

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2017)

Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2018)

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
por: Spagnolo, Francesco, et al.
Publicado: (2015)

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Pancreatic Cancer: From Genetic Mechanisms to Translational Challenges
por: Pastorino, Lorenza, et al.
Publicado: (2023)

Surveillance, CDKN2A and survival of familial melanoma
por: van Doorn, Remco
Publicado: (2023)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Melanoma‐specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non‐carriers
por: Pissa, Maria, et al.
Publicado: (2022)

Insights into Mechanisms of Tumorigenesis in Neuroendocrine Neoplasms
por: Pastorino, Lorenza, et al.
Publicado: (2021)

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom
por: Harland, Mark, et al.
Publicado: (2014)

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry
por: Bruno, William, et al.
Publicado: (2016)

TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear
por: Monti, Paola, et al.
Publicado: (2017)

Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients
por: Ciccarese, Giulia, et al.
Publicado: (2020)

Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in CDKN2A
por: Llach, Joan, et al.
Publicado: (2023)

Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients
por: Puccini, Alberto, et al.
Publicado: (2022)

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia
por: Dalmasso, B., et al.
Publicado: (2021)

Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer
por: Liu, Yaxuan, et al.
Publicado: (2022)

Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism
por: Mazarico-Altisent, I., et al.
Publicado: (2022)

Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome
por: Chan, Sock Hoai, et al.
Publicado: (2016)

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study
por: Davies, John R, et al.
Publicado: (2012)

Identification, genetic testing, and management of hereditary melanoma
por: Leachman, Sancy A., et al.
Publicado: (2017)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition
por: Chan, Sock Hoai, et al.
Publicado: (2021)

Regulation of male germline transmission patterns by the Trp53-Cdkn1a pathway
por: Kanatsu-Shinohara, Mito, et al.
Publicado: (2022)

Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting
por: Vanni, Irene, et al.
Publicado: (2023)

Early Onset Primary Hyperparathyroidism Associated with a Novel Germline Mutation in CDKN1B
por: Elston, Marianne S., et al.
Publicado: (2015)

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
por: Cabrita, Rita, et al.
Publicado: (2020)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

CDKN1A: A double-edged sword in fatty liver?
por: Valenti, Luca, et al.
Publicado: (2014)

Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study
por: Demenais, F., et al.
Publicado: (2010)

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
por: Helgadottir, Hildur, et al.
Publicado: (2018)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a CDKN2A germline mutation carrier
por: Martínez de Juan, Fernando, et al.
Publicado: (2017)

Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report
por: Jeong, Ah-Reum, et al.
Publicado: (2022)

A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved
por: Ghiorzo, Paola, et al.
Publicado: (2023)

Long Non-Coding RNAs and Metabolic Rewiring in Pancreatic Cancer
por: Dalmasso, Bruna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_37m1lid2o90vkku39lk87srs5g